Jean Bidlack - Publications

Affiliations: 
School of Medicine and Dentistry University of Rochester, Rochester, NY 
Area:
Biochemistry, Molecular Biology, Cell Biology

62 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Lefever M, Li Y, Anglin B, Muthu D, Giuvelis D, Lowery JJ, Knapp BI, Bidlack JM, Bilsky EJ, Polt R. Structural Requirements for CNS Active Opioid Glycopeptides. Journal of Medicinal Chemistry. 58: 5728-41. PMID 26125201 DOI: 10.1021/acs.jmedchem.5b00014  0.72
2014 Li Y, St Louis L, Knapp BI, Muthu D, Anglin B, Giuvelis D, Bidlack JM, Bilsky EJ, Polt R. Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin? Journal of Medicinal Chemistry. 57: 2237-46. PMID 24576160 DOI: 10.1021/jm400879w  0.72
2014 Sromek AW, Provencher BA, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL. Preliminary pharmacological evaluation of enantiomeric morphinans. Acs Chemical Neuroscience. 5: 93-9. PMID 24393077 DOI: 10.1021/cn400205z  0.72
2013 Provencher BA, Sromek AW, Li W, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors. Journal of Medicinal Chemistry. 56: 8872-8. PMID 24107104 DOI: 10.1021/jm401290y  0.72
2013 VanAlstine MA, Wentland MP, Alvarez J, Cao Q, Cohen DJ, Knapp BI, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 9: Synthesis, characterization and molecular modeling of pyridinyl isosteres of N-BPE-8-CAC (1), a high affinity ligand for opioid receptors. Bioorganic & Medicinal Chemistry Letters. 23: 2128-33. PMID 23434225 DOI: 10.1016/j.bmcl.2013.01.117  0.72
2013 Hoot MR, Sypek EI, Reilley KJ, Carey AN, Bidlack JM, McLaughlin JP. Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward. Behavioural Pharmacology. 24: 144-52. PMID 23412114 DOI: 10.1097/FBP.0b013e32835f3d2f  0.72
2012 Wentland MP, Jo S, Gargano JM, VanAlstine MA, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC. Bioorganic & Medicinal Chemistry Letters. 22: 7340-4. PMID 23142613 DOI: 10.1016/j.bmcl.2012.10.081  0.72
2012 Neumeyer JL, Zhang B, Zhang T, Sromek AW, Knapp BI, Cohen DJ, Bidlack JM. Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors. Journal of Medicinal Chemistry. 55: 3878-90. PMID 22439881 DOI: 10.1021/jm3001086  0.72
2012 Li Y, Lefever MR, Muthu D, Bidlack JM, Bilsky EJ, Polt R. Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins. Future Medicinal Chemistry. 4: 205-26. PMID 22300099 DOI: 10.4155/fmc.11.195  0.72
2012 Dean RL, Eyerman D, Todtenkopf MS, Turncliff RZ, Bidlack JM, Deaver DR. Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats. Pharmacology, Biochemistry, and Behavior. 100: 530-7. PMID 22056608 DOI: 10.1016/j.pbb.2011.10.019  0.72
2011 Yeomans L, Muthu D, Lowery JJ, Martinez HN, Abrell L, Lin G, Strom K, Knapp BI, Bidlack JM, Bilsky EJ, Polt R. Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environments. Chemical Biology & Drug Design. 78: 749-56. PMID 21801311 DOI: 10.1111/j.1747-0285.2011.01203.x  0.72
2011 Zhang B, Zhang T, Sromek AW, Scrimale T, Bidlack JM, Neumeyer JL. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors. Bioorganic & Medicinal Chemistry. 19: 2808-16. PMID 21482470 DOI: 10.1016/j.bmc.2011.03.052  0.72
2011 Zhang T, Yan Z, Sromek A, Knapp BI, Scrimale T, Bidlack JM, Neumeyer JL. Aminothiazolomorphinans with mixed κ and μ opioid activity. Journal of Medicinal Chemistry. 54: 1903-13. PMID 21351746 DOI: 10.1021/jm101542c  0.72
2011 Hough LB, Nalwalk JW, Yang J, Conroy JL, VanAlstine MA, Yang W, Gargano J, Shan Z, Zhang SZ, Wentland MP, Phillips JG, Knapp BI, Bidlack JM, Zuiderveld OP, Leurs R, et al. Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic. Pain. 152: 878-87. PMID 21316152 DOI: 10.1016/j.pain.2011.01.001  0.72
2011 Balboni G, Salvadori S, Marczak ED, Knapp BI, Bidlack JM, Lazarus LH, Peng X, Si YG, Neumeyer JL. Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic. European Journal of Medicinal Chemistry. 46: 799-803. PMID 21216504 DOI: 10.1016/j.ejmech.2010.12.001  0.72
2011 Lowery JJ, Raymond TJ, Giuvelis D, Bidlack JM, Polt R, Bilsky EJ. In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice. The Journal of Pharmacology and Experimental Therapeutics. 336: 767-78. PMID 21118955 DOI: 10.1124/jpet.110.172866  0.72
2010 Balboni G, Salvadori S, Trapella C, Knapp BI, Bidlack JM, Lazarus LH, Peng X, Neumeyer JL. Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore. Acs Chemical Neuroscience. 1: 155-164. PMID 20352071 DOI: 10.1021/cn900025j  0.72
2010 Fulton BS, Knapp BL, Bidlack JM, Neumeyer JL. Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorganic & Medicinal Chemistry Letters. 20: 1507-9. PMID 20144870 DOI: 10.1016/j.bmcl.2010.01.101  0.72
2010 Conroy JL, Fang C, Gu J, Zeitlin SO, Yang W, Yang J, VanAlstine MA, Nalwalk JW, Albrecht PJ, Mazurkiewicz JE, Snyder-Keller A, Shan Z, Zhang SZ, Wentland MP, Behr M, ... ... Bidlack JM, et al. Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nature Neuroscience. 13: 284-6. PMID 20139973 DOI: 10.1038/nn.2497  0.72
2010 Decker M, Si YG, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. Journal of Medicinal Chemistry. 53: 402-18. PMID 19928862 DOI: 10.1021/jm9013482  0.72
2009 Decker M, Fulton BS, Zhang B, Knapp BI, Bidlack JM, Neumeyer JL. Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. Journal of Medicinal Chemistry. 52: 7389-96. PMID 19634902 DOI: 10.1021/jm900379p  0.72
2009 Keyari CM, Knapp BI, Bidlack JM, Lowey J, Bilsky EJ, Polt R. Glycosyl-enkephalins: synthesis and binding at the mu, delta & kappa opioid receptors. Antinociception in mice. Advances in Experimental Medicine and Biology. 611: 495-6. PMID 19400281 DOI: 10.1007/978-0-387-73657-0_214  0.72
2009 Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, Ganorkar R, VanAlstine MA, Guo C, Cohen DJ, Bidlack JM. Syntheses of novel high affinity ligands for opioid receptors. Bioorganic & Medicinal Chemistry Letters. 19: 2289-94. PMID 19282177 DOI: 10.1016/j.bmcl.2009.02.078  0.72
2009 Wentland MP, Lu Q, Ganorkar R, Zhang SZ, Jo S, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: Syntheses and opioid receptor properties of cyclic variants of cyclazocine Bioorganic and Medicinal Chemistry Letters. 19: 365-368. PMID 19091564 DOI: 10.1016/j.bmcl.2008.11.076  0.72
2009 Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM. Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorganic & Medicinal Chemistry Letters. 19: 203-8. PMID 19027293 DOI: 10.1016/j.bmcl.2008.10.134  0.72
2008 Fulton BS, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors. Bioorganic & Medicinal Chemistry Letters. 18: 4474-6. PMID 18674902 DOI: 10.1016/j.bmcl.2008.07.054  0.72
2008 Mathews JL, Fulton BS, Negus SS, Neumeyer JL, Bidlack JM. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties. Neurochemical Research. 33: 2142-50. PMID 18528756 DOI: 10.1007/s11064-008-9752-3  0.72
2008 Wentland MP, Sun X, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine Bioorganic and Medicinal Chemistry. 16: 5653-5664. PMID 18417347 DOI: 10.1016/j.bmc.2008.03.066  0.72
2007 VanAlstine MA, Wentland MP, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4′-phenyl)-phenethyl) analogues of 8-CAC Bioorganic and Medicinal Chemistry Letters. 17: 6516-6520. PMID 17935988 DOI: 10.1016/j.bmcl.2007.09.082  0.72
2007 Zhang A, Li F, Ding C, Yao Q, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol. Journal of Medicinal Chemistry. 50: 2747-51. PMID 17488103 DOI: 10.1021/jm0701674  0.72
2007 Peng X, Knapp BI, Bidlack JM, Neumeyer JL. In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorganic & Medicinal Chemistry. 15: 4106-12. PMID 17433695 DOI: 10.1016/j.bmc.2007.03.076  0.72
2007 Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. Journal of Medicinal Chemistry. 50: 2254-8. PMID 17407276 DOI: 10.1021/jm061327z  0.72
2007 Lowery JJ, Yeomans L, Keyari CM, Davis P, Porreca F, Knapp BI, Bidlack JM, Bilsky EJ, Polt R. Glycosylation improves the central effects of DAMGO. Chemical Biology & Drug Design. 69: 41-7. PMID 17313456 DOI: 10.1111/j.1747-0285.2007.00462.x  0.72
2007 Peng X, Knapp BI, Bidlack JM, Neumeyer JL. High-affinity carbamate analogues of morphinan at opioid receptors. Bioorganic & Medicinal Chemistry Letters. 17: 1508-11. PMID 17276685 DOI: 10.1016/j.bmcl.2007.01.013  0.72
2006 Bidlack JM, Khimich M, Parkhill AL, Sumagin S, Sun B, Tipton CM. Opioid receptors and signaling on cells from the immune system. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 1: 260-9. PMID 18040803 DOI: 10.1007/s11481-006-9026-2  0.72
2006 Neumeyer JL, Peng X, Knapp BI, Bidlack JM, Lazarus LH, Salvadori S, Trapella C, Balboni G. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. Journal of Medicinal Chemistry. 49: 5640-3. PMID 16942040 DOI: 10.1021/jm0605785  0.72
2006 Wentland MP, VanAlstine M, Kucejko R, Lou R, Cohen DJ, Parkhill AL, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3- benzazocines. 4. Opioid receptor binding properties of 8-[n-(4′-phenyl)- phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine Journal of Medicinal Chemistry. 49: 5635-5639. PMID 16942039 DOI: 10.1021/jm060278n  0.72
2006 Nefzi A, Ostresh JM, Appel JR, Bidlack J, Dooley CT, Houghten RA. Identification of potent and highly selective chiral tri-amine and tetra-amine mu opioid receptors ligands: an example of lead optimization using mixture-based libraries. Bioorganic & Medicinal Chemistry Letters. 16: 4331-8. PMID 16750366 DOI: 10.1016/j.bmcl.2006.05.053  0.72
2006 Parkhill AL, Bidlack JM. Reduction of lipopolysaccharide-induced interleukin-6 production by the kappa opioid U50,488 in a mouse monocyte-like cell line. International Immunopharmacology. 6: 1013-9. PMID 16644488 DOI: 10.1016/j.intimp.2006.01.012  1
2006 Sun B, Tipton CM, Bidlack JM. The expression of prodynorphin gene is down-regulated by activation with lipopolysaccharide in U-937 macrophage cells. Journal of Neuroimmunology. 174: 52-62. PMID 16483672 DOI: 10.1016/j.jneuroim.2006.01.006  0.72
2006 Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. Journal of Medicinal Chemistry. 49: 256-62. PMID 16392810 DOI: 10.1021/jm050577x  0.72
2005 Zhen Z, Bradel-Tretheway B, Sumagin S, Bidlack JM, Dewhurst S. The human herpesvirus 6 G protein-coupled receptor homolog U51 positively regulates virus replication and enhances cell-cell fusion in vitro. Journal of Virology. 79: 11914-24. PMID 16140767 DOI: 10.1128/JVI.79.18.11914-11924.2005  0.72
2005 Mathews JL, Peng X, Xiong W, Zhang A, Negus SS, Neumeyer JL, Bidlack JM. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties. The Journal of Pharmacology and Experimental Therapeutics. 315: 821-7. PMID 16076937 DOI: 10.1124/jpet.105.084343  0.72
2005 Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30: 2254-62. PMID 15988468 DOI: 10.1038/sj.npp.1300811  0.72
2005 Wentland MP, Sun X, Bu Y, Lou R, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 3: 8-Thiocarboxamido and 8-thioformamido derivatives of cyclazocine. Bioorganic & Medicinal Chemistry Letters. 15: 2547-51. PMID 15863314 DOI: 10.1016/j.bmcl.2005.03.056  0.72
2005 Wentland MP, Lu Q, Lou R, Bu Y, Knapp BI, Bidlack JM. Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. Bioorganic & Medicinal Chemistry Letters. 15: 2107-10. PMID 15808478 DOI: 10.1016/j.bmcl.2005.02.032  0.72
2004 Stevenson GW, Wentland MP, Bidlack JM, Mello NK, Negus SS. Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys. European Journal of Pharmacology. 506: 133-41. PMID 15588733 DOI: 10.1016/j.ejphar.2004.10.051  0.72
2004 Zhen Z, Bradel-Tretheway BG, Dewhurst S, Bidlack JM. Transient overexpression of kappa and mu opioid receptors using recombinant adenovirus vectors. Journal of Neuroscience Methods. 136: 133-9. PMID 15183265 DOI: 10.1016/j.jneumeth.2004.01.009  0.72
2004 Csutoras C, Zhang A, Bidlack JM, Neumeyer JL. An investigation of the N-demethylation of 3-deoxymorphine and the affinity of the alkylation products to mu, delta, and kappa receptors. Bioorganic & Medicinal Chemistry. 12: 2687-90. PMID 15110850 DOI: 10.1016/j.bmc.2004.03.011  0.72
2004 Zhang A, Xiong W, Hilbert JE, DeVita EK, Bidlack JM, Neumeyer JL. 2-aminothiazole-derived opioids. Bioisosteric replacement of phenols. Journal of Medicinal Chemistry. 47: 1886-8. PMID 15055988 DOI: 10.1021/jm049978n  0.72
2004 Gekker G, Hu S, Wentland MP, Bidlack JM, Lokensgard JR, Peterson PK. κ-Opioid Receptor Ligands Inhibit Cocaine-Induced HIV-1 Expression in Microglial Cells Journal of Pharmacology and Experimental Therapeutics. 309: 600-606. PMID 14757849 DOI: 10.1124/jpet.103.060160  0.72
2004 Rusovici DE, Negus SS, Mello NK, Bidlack JM. Kappa-opioid receptors are differentially labeled by arylacetamides and benzomorphans. European Journal of Pharmacology. 485: 119-25. PMID 14757131 DOI: 10.1016/j.ejphar.2003.11.078  0.72
2004 Zhang A, Xiong W, Bidlack JM, Hilbert JE, Knapp BI, Wentland MP, Neumeyer JL. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors. Journal of Medicinal Chemistry. 47: 165-74. PMID 14695830 DOI: 10.1021/jm0304156  0.72
2004 Bidlack JM, Parkhill AL. Assay of G protein-coupled receptor activation of G proteins in native cell membranes using [35S]GTP gamma S binding. Methods in Molecular Biology (Clifton, N.J.). 237: 135-43. PMID 14501046  1
2003 Zhou Q, Duan WH, Cohen DJ, Bidlack JM, Wentland MP. Synthesis and pharmacology of 8-amino-3-[(tetrahydro-2-furanyl) methyl] benzomorphan Yaoxue Xuebao. 38: 748-753. PMID 14730897  0.72
2003 Neumeyer JL, Zhang A, Xiong W, Gu XH, Hilbert JE, Knapp BI, Negus SS, Mello NK, Bidlack JM. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors. Journal of Medicinal Chemistry. 46: 5162-70. PMID 14613319 DOI: 10.1021/jm030139v  0.72
2003 Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, Glick SD, Bidlack JM. Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. Journal of Medicinal Chemistry. 46: 2716-30. PMID 12801235 DOI: 10.1021/jm020562o  0.72
2003 Wentland MP, Sun X, Ye Y, Lou R, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 2: 8-Formamidocyclazocine analogues Bioorganic and Medicinal Chemistry Letters. 13: 1911-1914. PMID 12749896 DOI: 10.1016/S0960-894X(03)00295-6  0.72
2003 Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, Mello NK. Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 1125-39. PMID 12637953 DOI: 10.1038/sj.npp.1300105  0.72
2003 Wentland MP, Ye Y, Cioffi CL, Lou R, Zhou Q, Xu G, Duan W, Dehnhardt CM, Sun X, Cohen DJ, Bidlack JM. Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines Journal of Medicinal Chemistry. 46: 838-849. PMID 12593663 DOI: 10.1021/jm020429w  0.72
2002 Parkhill AL, Bidlack JM. Several delta-opioid receptor ligands display no subtype selectivity to the human delta-opioid receptor. European Journal of Pharmacology. 451: 257-64. PMID 12242086  1
2002 Bidlack JM, Cohen DJ, McLaughlin JP, Lou R, Ye Y, Wentland MP. 8-Carboxamidocyclazocine: A long-acting, novel benzomorphan Journal of Pharmacology and Experimental Therapeutics. 302: 374-380. PMID 12065740 DOI: 10.1124/jpet.302.1.374  0.72
Show low-probability matches.